Please ensure Javascript is enabled for purposes of website accessibility
Home > Information > BioSpotlight

Nature Breakthrough: PPP2R1A Mutations Boost Immunotherapy Survival in OCCC Patients

Release date: 2025-07-11 View count: 1

In the field of cancer immunotherapy, immune checkpoint inhibitors (ICBs) have revolutionized treatment for various solid tumors. However, ovarian cancer, particularly ovarian clear cell carcinoma (OCCC), shows a low response rate to ICBs, typically ranging from 5–15%. Commonly used biomarkers such as PD-L1 expression, tumor mutation burden (TMB), BRCA1/2 mutations, and homologous recombination deficiency (HRD) have not shown significant predictive value in OCCC. However, a recent study published in Nature suggests that a gene mutation in PPP2R1A could dramatically alter the prognosis for these patients.

Ovarian clear cell carcinoma (OCCC) is a tumor with poor prognosis and extremely low response rates to immunotherapy. In a clinical trial involving dual immune checkpoint inhibitors (ICBs), researchers unexpectedly found that some patients not only had extended survival but also showed high sensitivity to the treatment. Further analysis revealed that these patients’ tumors all carried PPP2R1A mutations, leading to strikingly different outcomes—their median overall survival reached 66.9 months, compared to just 9.2 months for patients without the mutation. This stark difference far exceeded expectations for the impact of a single gene mutation on treatment efficacy, prompting researchers to investigate the role of PPP2R1A in immunotherapy.

PPP2R1A Mutation Linked to Prolonged Survival in OCCC Patients Post-ICB

PPP2R1A encodes the main structural subunit of the PP2A complex, a serine/threonine phosphatase that regulates various cellular signaling pathways. In simple terms, it acts as a "balancer" in cells, suppressing overactive signaling pathways.

This study found that common PPP2R1A mutations (particularly R183W and R183Q) impair its binding to regulatory subunits, disrupting the function of the entire PP2A complex and activating several immune-related pathways. In other words, these mutations make cancer cells more "visible" to the immune system, increasing their susceptibility to immune attack.

Fig. 1. PPP2R1A mutation associated with prolonged survival in OCCC patients following ICB treatment

Enhanced Sensitivity of PPP2R1A-Mutant Tumors to T-Cell Killing and ICB Therapy

Further analysis of tumor RNA expression profiles and spatial immune phenotyping revealed significantly higher immune cell infiltration in tumors with PPP2R1A mutations. Specifically:

  • CD8⁺ memory T cells (CD45RO⁺PD-1⁻) accumulated at tumor margins
  • Increased numbers of MHC-II⁺ antigen-presenting cells
  • Marked increase in tertiary lymphoid structures (TLS)
  • Heightened activity of interferon-γ (IFNγ) and IL-2 signaling pathways

These changes indicate that PPP2R1A mutations not only alter the cancer cells themselves but also "activate" the tumor microenvironment, enhancing immune system engagement.

Fig. 2. PPP2R1A-mutant tumors show enhanced sensitivity to T-cell killing and immune checkpoint blockade therapy

Validation of PPP2R1A’s Role in Immunotherapy

If mutations can enhance immune responses, could artificially manipulating PP2A function achieve similar effects? The research team validated this through various models:

In vitro experiments showed that SKOV3 ovarian cancer cells with PPP2R1A knockdown or expressing the mutant form (P179R) were more sensitive to CAR-T cell killing. The PP2A inhibitor LB-100 further enhanced immune-mediated killing. CRISPR editing experiments confirmed at the genetic level that PPP2R1A mutations increase tumor cell sensitivity to T-cell attacks. Animal model results were consistent: in patient-derived xenografts (PDX) carrying PPP2R1A mutations and in allogeneic tumor models, the mutation significantly enhanced responses to immune checkpoint inhibitors (ICBs), suggesting its role as a key regulator of immune sensitivity both in vitro and in vivo.

Fig. 3. Flowchart showing the patient cohort and samples analyzed via translational methods

Broader Implications of PPP2R1A Mutations

Further data analysis reinforced these findings. The research team evaluated overall survival in 1,661 patients receiving ICB treatment across multiple public databases and found significantly longer survival in those with PPP2R1A mutations. In contrast, among 7,564 patients not receiving ICB treatment, mutation status was not associated with survival, suggesting that PPP2R1A mutations may be a specific predictive biomarker for ICB therapy. Similar trends were observed in independent cohorts of non-small cell lung cancer and melanoma, though sample sizes were small, and statistical significance has yet to be established.

In summary, PPP2R1A mutations may not only reveal a new mechanism of immunotherapy sensitivity but also provide a potential molecular tool for precision stratification in clinical immunotherapy.

abinScience PPP2R1A Research Tools

abinScience, specializes in developing high-quality research reagents. We are committed to providing innovative and reliable tools and technical solutions for life science researchers worldwide. Below is a list of abinScience’s PPP2R1A-related protein products. 

Catalog No. Product Name
HB105012 Recombinant Human PPP2R1A Protein, N-His
MB105012 Recombinant Mouse PPP2R1A Protein, C-His

For additional products, contact our specialists via support@abinscience.com.

Request product list: support@abinscience.com

Get a free quote